D-689-2013 Class III Terminated

Recalled by Teva Pharmaceuticals USA, Inc. — Sellersville, PA

FDA drug recall D-689-2013 was initiated by Teva Pharmaceuticals USA, Inc. on Mar 15, 2013 and is designated Class III. Reason for recall: Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing The recall status is terminated (terminated Jan 15, 2014). Affected quantity: 154,536 cartons.

Recall details

Product Type
Drugs
Report Date
Jul 17, 2013
Initiation Date
Mar 15, 2013
Termination Date
Jan 15, 2014
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
154,536 cartons

Product description

Errin (norethindrone tablets, USP), 0.35 mg, 6 blister cards per carton, 28 tablets each, 28 day regimen, Rx Only, Teva Pharmaceuticals USA, Sellersville, PA 18960, NDC 0555-0344-58

Reason for recall

Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing

Distribution pattern

Nationwide and Puerto Rico

Code information

Lot #s: 33801773A, Exp 7/14; 33801774A, Exp 8/14; 33801775A, 33801776A, Exp 9/14; 33802427A, 33802428A, 33802429A, 33802430A, Exp 12/14; 33802925A, 33802926A, Exp 3/15; 33803383A, 33803384A, 33803385A, 33803387A, 33803685A, Exp 6/15.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-689-2013
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-689-2013. Report a data issue: hello@regdatalab.com.